Clinical Trials

The proposed research study will provide preliminary evidence of the potential to utilize [F-18]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.

This study is evaluating the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB.

The investigators are doing this research study to compare whole body aerobic training with isolated leg training (with weights) and its impact on effectiveness in symptoms and quality of life in patients with Pulmonary Arterial Hypertension (PAH).

Has your doctor recommended right heart cardiac catheterization for you? This study is investigating new magnetic resonance imaging (MRI) techniques that use a guidewire to help position a heart catheter within the heart. MRI fluoroscopy shows pictures of the heart so that doctors can watch while they work. Using the guidewire during MRI may improve the procedure of heart catheterization. To participate in this study, you must be at least 18 years old, and your doctor must have recommended right heart catheterization for you. This study is located in Bethesda, Maryland.

Are you an adult interested in a new treatment for pulmonary hypertension? This study is exploring whether a medicine called spironolactone can improve heart and lung function during exercise in people who have pulmonary hypertension. To participate in this study, you must be 18 to 99 years old and have a type of pulmonary hypertension known as pulmonary arterial hypertension. This study is located in Bethesda, Maryland.

Do you or a family member have pulmonary hypertension? This study is looking at how hormones contribute to pulmonary arterial hypertension and whether treatments for hormone imbalances or insulin resistance also improve pulmonary hypertension. To participate in this study, you must be 90 years old or younger and have pulmonary arterial hypertension or be a family member of someone who has this condition. This study is located in Nashville, Tennessee.

Este estudio explora si un medicamento llamado espironolactona puede mejorar la función cardíaca y pulmonar durante el ejercicio en personas con hipertensión pulmonar. Para participar en este estudio, debe tener entre 18 y 99 años y un tipo de hipertensión pulmonar conocido como hipertensión arterial pulmonar. Este estudio se lleva a cabo en Bethesda (Maryland).

Are you an adult with pulmonary arterial hypertension (PAH) and currently taking vasodilators? This study is testing the efficacy of a new medicine called famotidine for people with PAH. Participants in this study must be between 18 and 80 years old and willing to take famotidine or a placebo for 6 months. This study takes place in Seattle, Washington.